Clinical Trial

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

Study acronym: ICONIC-ASCEND
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.
Protocol Amendment History 1 change
notable Primary completion moved earlier: 2026-03-30 -> 2025-11-17 2026-04-14
Trial Details
NCT Number NCT06934226
Lead Sponsor Janssen Research & Development, LLC
Conditions Plaque Psoriasis
Enrollment 752 participants
Start Date 2025-04-15
Primary Completion 2025-11-17 (estimated)
Study Completion 2027-08-20 (estimated)
Updated on ClinicalTrials.gov 2026-07-31